Healight Ultraviolet Endotracheal Device Has Covid-19 Treatment Potential
The Healight Medical Device Platform Technology is under research development at Cedars-Sinai hospital by Aytu Biomedical.
This medical device technology platform, discovered and
developed by scientists at Cedars-Sinai, is being studied as a potential
first-in-class treatment for coronavirus and other respiratory infections.
Led by Mark Pimentel, MD, the research team of the Medically Associated
Science and Technology (MAST) Program at Cedars-Sinai has been developing the
patent-pending Healight platform since 2016 and has produced a growing body of
scientific evidence demonstrating pre-clinical safety and effectiveness of the
technology as an antiviral and antibacterial treatment. The Healight
technology employs proprietary methods of administering intermittent
ultraviolet (UV) A light via a novel endotracheal medical device. Pre-clinical
findings indicate the technology's significant impact on eradicating a wide
range of viruses and bacteria, inclusive of coronavirus. The data have been
the basis of discussions with the FDA for a near-term path to enable human use
for the potential treatment of coronavirus in intubated patients in the
intensive care unit (ICU). Beyond the initial pursuit of a coronavirus ICU
indication, additional data suggest broader clinical applications for the
technology across a range of viral and bacterial pathogens. This includes
bacteria implicated in ventilator associated pneumonia (VAP).
"Our team has shown that administering a specific spectrum of UV-A light can
eradicate viruses in infected human cells (including coronavirus) and bacteria
in the area while preserving healthy cells," stated Dr. Pimentel of
Cedars-Sinai. Ali Rezaie, MD, one of the inventors of this technology states,
"Our lab at Cedars-Sinai has extensively studied the effects of this unique
technology on bacteria and viruses. Based on our findings we believe this
therapeutic approach has the potential to significantly impact the high
morbidity and mortality of coronavirus-infected patients and patients infected
with other respiratory pathogens. We are looking forward to partnering with
Aytu BioScience to move this technology forward for the benefit of patients
all over the world."
She handed him the tiny cutting tool. He made a clean incision through the tissue that had closed in around the barbs, the beam cauterizing as it cut. Then, grasping hold of the short, splintered stub, he gently pulled the head out.
"Sara, anabolic protoplaser, type zero."
He applied the tip of the instrument to the interior of the wound, slowly working it outward to repair torn veins and gashed arteries, and unite nerves and muscle fibers. Soon, all that was left was the closing of the jagged tear where the spear had gone in and the small incision below it.
"Type two protoplaser."
Scroll down for more stories in the same category. (Story submitted 10/5/2020)